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Surface expression of CD4 or CD8 is commonly used
to identify T-cell subsets that recognize antigen
presented by class II MHC or class I MHC, respectively.
This holds true for T cells that respond to allogeneic
MHC molecules that are directly recognized as
foreign, as well as peptides from allogeneic MHC
molecules that are indirectly presented by self MHC
molecules. CD4 or CD8 expression was initially
believed to define cytokine secreting helper T cells
or cytotoxic cells, respectively. However, this associa-
tion of phenotype and function is not absolute, in that
CD4+ cells may possess lytic activity and CD8+ cells
secrete cytokines, notably IFNg. Recently, additional
fundamental differences in the immunobiology of
these T-cell subsets have been identified. These
include differences in costimulatory requirements,
cytokine responsiveness, cytokine production, cell
survival, and the maintenance of memory. This review
will survey these differences, emphasizing alloreac-
tive T-cell responses as well as relevant observations
that have been made in other systems.
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Functions of CD4 and CD8
The concept that subpopulations of T cells could be delin-
eated by specific cell surface markers was first estab-
lished in 1975 by Cantor and Boyse (1), who defined
murine T-cell subsets based on Lyt1 and Lyt2 antigens.
Their work, and subsequent independent studies with
both mouse and human cell lines established that this
phenotypic difference between T cells had a functional
importance as well, since helper CD4þ T cells (L3T4)
responded exclusively to antigens (Ag) presented by class II
MHC, while CD8 (Lyt2) cytotoxic T cells recognized Ag in
the context of class I MHC presentation (2–5). Indeed,
monoclonal antibodies (mAb) specific for CD8 and CD4
blocked T-cell interactions with class I and class II MHC–Ag
complexes, indicating an essential role for CD4 and CD8
as coreceptors for T-cell receptor (TCR) recognition of Ag in
the context of MHC [reviewed in (6)]. Both coreceptors
bind to their respective MHC molecule at sites distal from
the polymorphic antigen binding domains: CD4 binds to the
b2 domain of MHC class II, while the binding site of CD8
has been mapped to the a3 domain of MHC class I.
Coreceptor involvement with TCR engagement increases
the affinity of the TCR for Ag-MHC complexes, thereby
enhancing the activation of T cells 100-fold or more (7).
Though CD4 and CD8 both mediate coreceptor function
and are members of the immunoglobulin superfamily,
their structures differ greatly from one another. CD4 is
a 55–60-kDa monomeric glycoprotein consisting of 4
immunoglobulin-like domains with a flexible hinge between
the second and third domains (7,8). In contrast, CD8 is
expressed as a disulfide-linked homodimer of two a chains
(38 kDa) or as a heterodimer of a and b chains (28–30 kDa),
with each chain containing one immunoglobulin-like
domain (8). The CD8 isoforms are expressed in specific
contexts, with thymocytes and peripheral T cells express-
ing CD8ab, while intraepithelial lymphocytes in gut
express either CD8aa or CD8ab (9,10). CD4 and CD8
exert their coreceptor function through their association
with p56lck (Lck), a SRC family tyrosine kinase that phos-
phorylates several intracellular substrates, thereby initiat-
ing the signaling cascade of T-cell activation. Lck itself is
positively regulated by the common leukocyte antigen,
CD45. Signaling through CD45 activates a tyrosine phos-
phatase, which then dephosphorylates a COOH-terminal
tyrosine that negatively regulates Lck function. Engage-
ment of the TCR activates Lck, which in turn phosphoryl-
ates the immunoreceptor tyrosine-based activation motifs
(ITAMS) located at the cytoplasmic tail of the CD3 chains.
This allows for binding of the Syk family protein kinase
ZAP 70 to the z chains of the TCR, thus providing protein
kinase function for the TCR itself, which results in a series
of second messenger cascades (11). However, activation
of Lck through CD4 and CD8 is highly regulated and can
be affected by the isoform of CD45 expressed by the
T cell, the length of contact between Ag and TCR, and the




presence of costimulatory molecules such as CD28
(6,7,12). Fundamental differences in CD4 and CD8 struc-
ture also play a role, as signaling initiated through CD4 or
CD8ab results in a greater activation of Lck than signaling
through CD8aa (6,7). In addition, CD8 association with Lck
appears to play an important role in the rapid activation of
effector and memory T lymphocytes (13).
Recent studies have demonstrated a role for CD4 and
CD8 coreceptors in lipid raft formation. These rafts,
which are rich in cholesterol and glycosphingolipids,
seclude specific proteins while excluding others, and
serve as platforms on the plasma membrane to facilitate
signaling (14). The sequestering of Lck within lipid rafts in
particular appears to regulate activation of the cell. For
instance, formation of lipid rafts stabilizes the association
of CD8 and Lck (15). Importantly, CD45 is excluded from
rafts, and its tyrosine phosphatase activity may activate
only coreceptor-associated Lck sequestered at the edge
of lipid rafts (14). In fact, visualization of immune synapse
formation showed that active Lck is only detected at the
periphery of synapse formation (16). The role of Lck and
coreceptors in the TCR mediated signaling appears to be
brief, since activated Lck and CD4 are no longer visualized
in the mature immune synapse (16,17).
CD8+ T Cells Have Survival Advantages Over
CD4+ T Cells
In both mouse (18) and man (19), cardiac allograft rejection
is characterized by the dominant presence of CD8þ cells
over CD4þ cells among graft infiltrating cell (GIC) popula-
tions. This may reflect preferential expansion of donor-
specific CD8þ cells in secondary lymphoid tissues (18) as
well as preferential apoptosis of CD4þ cells among the
GIC (19). Whether preferential recruitment and/or reten-
tion (20,21) of CD8þ cells contributes to this dominance
has not been established. The CD8þ GIC enrichment may
also be due to the fact that CD8þ cells have a selective
survival advantage over CD4þ cells. In infectious disease
models, CD8þ cells have been shown to have a greater
proliferative capacity than CD4þ cells (22) and may continue
to proliferate once the antigenic stimulus has been
removed (23). Further, CD8þ, but not CD4þ cells, may
undergo ‘bystander’ activation in response to bacterial
pathogens (24). Indeed, CD4þ cells appear to have an
intrinsically lower capacity for survival in general, which is
reflected by their gradual disappearance in thymectomized
animals and an increased sensitivity to apoptosis relative to
CD8þ cells (25). This is further emphasized by the finding
that virus-specific memory CD8þ cells persist in stable
numbers, whereas memory CD4þ cells decline with time
(26). The persistence of memory CD8þ cells is likely due to
high-level expression of the anti-apoptotic protein Bcl-2
(27). Collectively, these observations indicate that CD8þ
cells are generally ‘heartier’ than their CD4þ counterparts.
CD4+ and CD8+ T-Cell Interactions
Following the historic association of T-cell phenotype and
function (1–5), the concept that CD4þ cells provided the
necessary ‘help’ for CD8þ CTL received support from a
number of experimental systems (28–37). The nature of
the help provided by CD4þ cells for CD8þ CTL expansion
and development has been attributed to IL-2 production
(28) and CD40 ligand (CD40L) expression (35,36) by CD4þ
cells. CD40L expression by CD4þ cells is believed to acti-
vate CD40 expressing APC, thereby enhancing their
stimulatory capacity for CD8þ CTL (35,36). This notion of
CD4þ and CD8þ cell interactions was applied to allograft
rejection, where it became widely accepted that graft-
reactive CD8þ CTL served as the terminal effector cell
in the rejection response, while CD4þ cells provided the
signals required for CTL development and expansion
[reviewed in (38)]. This paradigm was supported by stud-
ies where in vivo treatment with anti-CD4 mAb markedly
prolonged allograft survival (18,39–42). Indeed, transient
depletion of CD4þ cells in cardiac allograft recipients elim-
inates IL-2 producing helper cells, prevents CTL activation,
and eliminates the development of intragraft inflammatory
endothelia, which is required for mononuclear cell infiltra-
tion into the graft (18). However, it should be noted that
CD8þ effector cells may develop independently of CD4þ
help, and that this process may be influenced by the route
of Ag delivery (43), the frequency of the CD8þ effector
cells (44,45), and the avidity of the TCR for Ag (46). CD4-
independent CD8 responses have been reported in models
of contact hypersensitivity (47), autoimmune diabetes
(48), tumor rejection (49), and islet xenograft rejection
(50), indicating that this phenomenon is widespread.
We reported that IFNg-deficient (IFNg –/–) cardiac allograft
recipients develop CD4-independent CD8þ effector cells
that are insensitive to treatment with anti-CD40L mAb
(51). This contrasts with cardiac allograft rejection in
wild-type (WT) recipients, which is prevented by treat-
ment with either anti-CD4 or anti-CD40L mAb. Treatment
of WT allograft recipients with anti-CD4 or anti-CD40L
mAb prevents CD8þ cell activation, yet allows these
cells to be maintained in a quiescent precursor state
(18,52). It is of interest that CD8þ cells represent a major
source of IFNg in WT cardiac allograft recipients (53), yet
the removal of this Th1 cytokine markedly influences the
behavior of CD8þ effector cells, making them much more
difficult to suppress. Unlike their CD8þ counterparts,
CD4þ effector cells in IFNg –/– mice are readily sup-
pressed by anti-CD40L therapy (51). Similar observations
were made by Newell et al. (54), who identified costimula-
tion blockade-resistant CD8þ, but not CD4þ cells in an
intestinal transplant model using IFNg sufficient CD4 –/– vs.
CD8 –/– mice as recipients. In this system, membrane
lymphotoxin (LT) serves as a critical effector molecule,
in that blocking membrane LT with a LT receptor
fusion protein inhibits rejection (55). Hence, under certain
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circumstances CD4-independent, costimulation blockade-
resistant CD8þ cells emerge that may be less susceptible
to immunosuppressive therapies than are CD4þ cells.
Whether these cells represent a distinct or differentiated
subset of CD8þ cells is not known; however, costimula-
tion blockade-resistant CD8þ cells have been reported to
express the surface marker, asialo GM1 (56). It should
also be noted that the appearance of costimulatory
blockade-resistant CD8þ cells may be influenced by the
mouse strain employed as the transplant recipient. Indeed,
Williams et al. (57) demonstrated that C57BL/6, but not
C3H/HeJ mice develop costimulation blockade-resistant
CTL and IFNg-producing cells following skin grafting.
The idea that the CD8þ CTL represents ‘the’ terminal
effector cell in allograft rejection (38) was initially called
into question by several reports that documented that
CD4þ cells could mediate rejection independently of
CD8þ cells (58–62). The mechanism(s) by which CD4þ
T cells mediate rejection have not been completely defined,
but polarized CD4þ cells that secrete either IFNg (Th1) or
IL-4 (Th2) are equally effective at inducing cardiac allograft
rejection (63). CD4þ Th1 likely mediate tissue damage
through a delayed type hypersensitivity (DTH) response
(64), as well as by promoting graft infiltration and
up-regulating the graft’s MHC for immune recognition by
graft reactive T cells (65). However, the mechanisms by
which CD4þ Th2 mediate rejection are less clear. We have
reported that depletion of CD8þ cells induces Th2 cytokine
production by CD4þ cells within cardiac allografts, which
is associated with the accumulation of eosinophils in the
transplant (59). Eosinophils and Th2 cytokines are not
readily detectable in unmodified cardiac allograft rejection,
where CD8þ cells and Th1 cytokines dominate the
response (18,53,59). This observation was further
explored by Braun et al. (66), who reported that IFNg
production by CD8þ cells inhibited IL-5 production by
CD4þ cells, which was responsible for the eosinophilia
within rejecting cardiac transplants. Hence, CD8þ cells
may negatively regulate cytokine production by CD4þ
cells. CD8þ cells that have been polarized to produce
Th2 cytokines also mediate cardiac allograft rejection,
which is characterized by an eosinophil influx (67). Further,
the CD4-independent, anti-CD40L-resistant CD8þ cells
that mediate cardiac allograft rejection in IFNg –/– mice
recruit numerous eosinophils and neutrophils into the
graft (51). However, eosinophils are not necessary for
rejection in the IFNg –/– mouse, since neutralizing
IL-4 abrogates eosinophil accumulation but does not
prevent rejection (51). Mechanisms by which eosinophils
may contribute to acute allograft rejection have been
recently reviewed (68), and eosinophils have been
implicated in chronic skin allograft rejection as well (69).
Hence, it appears that Th2 cytokine production by either
CD4þ or CD8þ cells results in ‘nontraditional’ mechanisms
of graft rejection, thereby detracting from the once
popular idea that Th2 may be beneficial in the context of
transplantation (70).
Collectively, these observations raise important points
regarding CD4þ/CD8þ T-cell interactions in transplant-
ation: First, transplant immunologists are accustomed to
the processes by which CD4þ cells regulate CD8þ T-cell
behavior and the rejection response [reviewed in (71)].
However, we are just beginning to understand CD8þ
T-cell regulation of CD4þ cell behavior and how this may
influence the composition of GIC. Second, under certain
conditions, CD8þ T cells have a mind of their own and
often choose not to play by what we view as the immuno-
logic rules.
Cytokine Regulation of CD4+ and CD8+
T Cells
Since the initial description of mouse CD4þ Th1 and Th2
clones (72), it has been well established that polarized
IFNg-producing Th1 and IL-4-producing Th2 may be
induced from heterogeneous populations of cells in both
mouse and man [reviewed in (73–75)]. While this was
originally found with CD4þ cells, it became apparent that
CD8þ T cells could also assume these polarized pheno-
types (76). Several factors are involved in Th1 vs. Th2
differentiation, and the local cytokine milieu markedly
influences which phenotype a T cell will adopt: IL-12 and
IFNg favor Th1 and IL4 favors Th2 development (74,75).
The down-stream regulators or ‘master switches’ for Th1
and Th2 development are the transcription factors T-bet
and GATA-3, respectively [reviewed in (75)]. GATA-3 is
strongly associated with Th2 differentiation, IL-4 produc-
tion and Stat 6 activation, and is not expressed in Th1 cells
(77–79). T-bet is expressed in Th1, but not Th2, and leads
to strong transactivation of the IFNg gene (80). Indeed,
transduction of T-bet into polarized Th2 converts these
cells into IFNg-producing Th1 and represses IL-4 and IL-5
production (80).
We have reported that alloreactive CD8þ cells do not
require biologically active IL-12p70 to differentiate into
IFNg-producing Th1 (53), suggesting that the Th1 pheno-
type represents the default pathway for CD8þ cells.
Indeed, CD8þ cells do not require signaling through Stat 4
for IFNg production when stimulated through the TCR,
whereas CD4þ cells do (81). Several factors may be
involved in the predisposition of CD8þ cells to acquire the
Th1 phenotype. For example, the IFNg promoter has been
shown to remain demethylated for prolonged periods
of time in CD8þ cells, even in the absence of repeated
TCR stimulation, favoring transcription of the IFNg gene
(82). Further, the IL-18 receptor (IL-18R) has been
reported to be expressed at higher levels on CD8þ cells
than on CD4þ cells (83). Since IL-18 shares Th1-inducing
activity with IL-12 [reviewed in (84)], preferential expres-
sion of IL-18R by CD8þ cells over CD4þ cells may explain
the differential responsiveness of these T-cell subsets to
this cytokine (85). Specifically, adding IL-18, but not IL-12
to primary mixed lymphocyte cultures (MLC) results in
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preferential expansion of CD8þ cells that produce 20- to
30-fold more IFNg upon secondary stimulation (85).
Finally, while the p40 subunit of IL-12 is antagonistic for
biologically active IL-12p70 on cells that have been stimu-
lated with mitogens or exogenous Ag (86), several reports
indicate that IL-12p40 may be stimulatory (53,87–89).
Indeed, we have found that alloreactive CD8þ cells
respond to IL-12p40 with increased IFNg production both
in vitro (87) and in vivo (53). Using p35 –/– and p40 –/– mice
as cardiac allograft recipients, we found that IL-12p40 may
substitute for IL-12p70 in promoting IFNg-producing CD8þ
cells (53). While not yet tested, it is interesting to specu-
late that these in vivo effects of IL-12p40 may result from
the ability of p40 to complex with p19, yielding the com-
posite cytokine IL-23 (90). Similarly to IL-12, IL-23 stimu-
lates IFNg production. If IL-23 mediates the stimulatory
effects of p40 on IFNg production in vivo, our observations
(53) would predict that IL-23 has preferential activity on
alloreactive CD8þ T cells over CD4þ cells.
Glimcher’s group recently reported that the Th1-inducing
transcription factor T-bet is required for IFNg production by
CD4þ and NK cells, but not by CD8þ cells (91). This very
interesting observation sheds further light on why CD8þ
cells acquire such a recalcitrant Th1 phenotype that is not
dependent on IL-12p70 (53) or Stat 4 activation (81).
Further piecing the puzzle together is a recent report
from Flavell’s group (92), which demonstrates that the
Th1-inhibiting activity of TGFb (93) is likely due to the
ability of TGFb to inhibit T-bet expression. Since CD4þ,
but not CD8þ cells are dependent on T-bet for IFNg pro-
duction, it now makes biologic sense that CD4þ and CD8þ
cells exhibit differential sensitivity to TGFb. Lotz et al. (94)
reported that human CD4þ clones are more sensitive than
their CD8þ counterparts to the antiproliferative effects of
TGFb. Further, we reported (95) that cardiac allograft
rejection by CD4þ cells is prevented by TGFb gene trans-
fer, whereas CD8þ cells are resistant to this therapy.
Interestingly, the protective effects of TGFb gene therapy
are associated with muted Th1 responses, and the pro-
tective effects on graft survival can be overridden by recipi-
ent treatment with exogenous IL-12 (95).
Finally, it appears that CD8þ cells are more dependent on
IL-15 as a growth and maintenance factor than their CD4þ
counterparts [reviewed in (96)]. IL-15 is structurally related
to IL-2 and signals through the IL-2R b and g chains com-
plexed with an IL-15 specific a chain [reviewed in (97)].
While IL-15 shares the T-cell growth factor (TCGF) activity
of IL-2, IL-15 is biologically distinct from IL-2 in several
ways (96,97). Unlike IL-2, IL-15 is produced by a variety of
cells types, but not by activated T cells. In addition, IL-15,
rather than IL-2, is required for the generation of primary
CD8þ effector cells during viral infections and the main-
tenance of CD8, but not CD4þ memory cells (98–101).
Unlike IL-2, IL-15 plays a role in homeostatic lymphocyte
recirculation (102) and may promote the survival of acti-
vated lymphocytes, as opposed to promoting activation-
induced cell death (AICD) (103). In the context of trans-
plantation, IL-15, rather than IL-2, is the TCGF most fre-
quently associated with rejection when human renal
biopsies are assessed for these cytokine transcripts
(104). Further, an antagonistic IL-15 fusion protein pre-
vents costimulation blockade-resistant rejection of allo-
geneic islets by CD8þ cells (105), and an antagonistic
soluble fragment of the IL-15Ra chain markedly prolongs
survival of minor Ag mismatched cardiac allografts (106).
In summary, the cytokine requirements for the growth,
maintenance, and function of CD4þ and CD8þ T cells are
quite dissimilar. Given this, it comes as no surprise that
selective cytokine manipulation aimed at preventing allograft
rejection by CD4þ and CD8þ T cells has met with limited
success. Indeed, manipulating cytokines combined with the
depletion of either CD4þ (106) or CD8þ (95) T cells has
proven necessary in experimental cardiac transplantation.
Costimulatory Requirements for CD4+ and
CD8+ T Cells
The importance of T-cell costimulation in allograft rejection
has been studied extensively [reviewed in (107–111)].
Hence, we will briefly highlight differences in costimula-
tory requirements for CD4þ and CD8þ cells here. While
costimulation blockade resistance is a recurring phenom-
enon for alloreactive CD8þ cells, this does not appear to
be the case for CD4þ cells (51,54–56,112). These studies
have examined the relative resistance of CD8þ cells to
blockade of the CD28/B7 and/or the CD40/CD40L path-
ways, and similar observations have been made in TCR
transgenic systems (113), in models of bacterial (114,115)
and viral (116,117) infection, and in TNFa-mediated dia-
betes (118). Yet conflicting reports exist, which demon-
strate a strict dependency on costimulation in CD8þ
effector cell development (35,36,119–121). The explanation
for costimulation dependence or independence of CD8þ
cells may lie in the strength and persistence of the stimu-
lating Ag. Indeed, Andreasen et al. (122) compared the
costimulation dependency of CD8þ cells during infection
with lymphocytic choriomeningitis virus (LCMV), which
replicates widely and extensively, and vesicular stomatitis
virus (VSV), which spreads poorly in mice. This study
demonstrated that the primary CD8þ effector cell response
to LCMV did not require CD40L or CD28, whereas the
CD8 (and CD4) response to VSV was markedly impaired.
While the CD28/B7 and CD40/CD40L pathways have
received the most attention in transplantation, other costimu-
latory molecules may contribute to effector cell devel-
opment and graft rejection [reviewed in (123)]. Of these,
4–1BB (CD137) and 4–1BBL have been implicated in the
development of CD8þ T cells [reviewed in (124)].
4–1BB and 4–1BBL are members of the TNFR and TNF
superfamilies, respectively. 4–1BB is primarily expressed
on activated T cells and 4–1BBL is expressed on mature
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dendritic cells (DC), activated B cells, and activated macro-
phages (123,124). Since 4–1BB and 4–1BBL expression
on resting cells is low or absent, it is believed that the
4–1BB/4–1BBL pathway plays a minor role in early activation
events in vivo. Indeed, stimulatory, agonistic mAb to
4–1BB have a greater effect on activated T cells than on
resting T cells (125), indicating that 4–1BB may play a
role in costimulation of T cells once CD28 has been
down regulated (126). Shuford et al. (127) reported that
costimulation though 4–1BB stimulates CD8þ cells to a
greater extent than CD4þ cells, while the converse holds
true for CD28 costimulation. Further, in vivo treatment
with stimulatory anti-4–1BB mAb amplifies H-2d-specific
CTL responses in a graft vs. host disease (GVHD) model,
and accelerates cardiac and skin allograft rejection (127).
Subsequent reports documented that 4–1BB ligation
favors the survival of CD8þ over CD4þ cells following
superantigen stimulation (128), and that 4–1BBL –/– mice
mount poor CD8þ but normal CD4þ T-cell responses to
LCMV infection (129,130). While both CD4þ and CD8þ
cells express 4–1BB following allogeneic stimulation in
MLC, 4–1BB ligation augments proliferation and IFNg pro-
duction by CD8þ cells to a greater extent than CD4þ cells
(131). Collectively, these studies suggest that 4–1BB is
involved in costimulation of CD8þ cells and plays only a
minor role in CD4þ cell activation. However, contrasting
reports indicate that 4–1BB ligation serves to costimulate
both CD4þ and CD8þ T cells (132–134), inducing IL-4
production from CD4þ cells and IFNg production from
CD8þ cells (133). Hence, differential utilization of the
4–1BB/4–1BBL costimulatory pathway by CD4þ vs.
CD8þ cells is controversial, and the involvement of
this pathway in transplant rejection remains to be
resolved.
Concluding Remarks
In summary, it appears that CD4þ and CD8þ T cells
have more dissimilarities than similarities. These differ-
ences are summarized in Table 1, along with relevant
references that support conflicting results. Hence, it
seems that the initial reports by Cantor and Boyse (1,2)
that T-cell phenotype correlates with function were cor-
rect. However, this association between phenotype and
function is much more complex than we had originally
envisioned. Rather than simply defining cells with lytic
(CD8þ) or helper (CD4þ) function, it is now apparent
that these T-cell subsets have differential costimulatory
and cytokine requirements for their maturation into
effector cells.
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Table 1: Summary of differences in CD4þ and CD8þ T-cell biology. Conflicting observations are noted by italics
CD4þ T cells CD8þ T cells Selected References
Cytokine requirements
IL-12p70 required for Th1 polarization Yes No (53)
Signaling through Stat-4 required Yes No (81)
IL-12p40 responsive No Yes (53,87–89)
Yes (88)
IL-18R expressed Low High (83)
T-bet required for IFNg production Yes No (91)
TGFb suppression Yes No (94,95)
Require IL-15 for growth No Yes (96–102)
Costimulatory requirements
CD28/B7 dependent Yes No (54,56,112–114,116)
Yes (122)
CD40/CD40L dependent Yes No (51,56,115,117,118)
Yes (35,36,119--122)
4–1BB/4–1BBL responsive No Yes (127–131)
Yes (132--134)
Roles in transplant rejection
Mediate CTL function No Yes (18,38,58,61)
Regulate CTL development Yes No (18,38)
Regulate CTL entry into the graft Yes No (18)
DTH response Yes Yes (38,61,63)
Promote eosinophil infiltration Yes (Th2) No (59)
Yes, if Th2 (51,67)
Contrasting Alloreactive CD4+ and CD8+ T Cells
American Journal of Transplantation 2003; 3: 107--115 111
References
1. Cantor H, Boyse EA. Functional subclasses of T-lymphocytes
bearing different Ly antigens. I. The generation of functionally
distinct T-cell subclasses is a differentiative process independent
of antigen. J Exp Med 1975; 141: 1376–1389.
2. Cantor H, Boyse EA. Functional subclasses of T lymphocytes
bearing different Ly antigens. II. Cooperation between subclasses
of Lyþ cells in the generation of killer activity. J Exp Med 1975;
141: 1390–1399.
3. Kelso A, MacDonald HR. Precursor frequency analysis of
lymphokine-secreting alloreactive T lymphocytes. Dissociation
of subsets producing interleukin 2, macrophage-activating factor,
and granulocyte-macrophage colony-stimulating factor on the
basis of Lyt-2 phenotype. J Exp Med 1982; 156: 1366–1379.
4. Engleman EG, Benike CJ, Grumet FC, Evans RL. Activation of
human T lymphocyte subsets: helper and suppressor/cytotoxic
T cells recognize and respond to distinct histocompatibility
antigens. J Immunol 1981; 127: 2124–2129.
5. Dialynas DP, Wilde DB, Marrack P et al. Characterization of the
murine antigenic determinant, designated L3T4a, recognized by
monoclonal antibody GK1.5: expression of L3T4a by functional
T cell clones appears to correlate primarily with class II MHC
antigen-reactivity. Immunol Rev 1983; 74: 29–56.
6. Ravichandran KS, Pratt JC, Sawasdikosol S, Irie HY, Burakoff SJ.
Coreceptors and adapter proteins in T-cell signaling. Ann N Y Acad
Sci 1995; 766: 117–133.
7. Janeway CA, Jr. The T cell receptor as a multicomponent signal-
ling machine: CD4/CD8 coreceptors and CD45 in T cell acti-
vation. Annu Rev Immunol 1992; 10: 645–674.
8. Parnes JR. Molecular biology and function of CD4 and CD8. Adv
Immunol 1989; 44: 265–311.
9. Guy-Grand D, Cerf-Bensussan N, Malissen B, Malassis-Seris BM,
Briottet C, Vassalli P. Two gut epithelial CD8þ lymphocyte popu-
lations with different T cell receptors: a role for the gut epithelium
in T cell differentiation. J Exp Med 1991; 173: 471–481.
10. Lefancois L. Phenotypic complexity of intraepithelial lympho-
cytes of the small intestine. J Immunol 1991; 147: 1746–1751.
11. Singer AL, Koretzky GA. Control of T cell function by positive and
negative regulators. Science 2002; 296: 1639–1640.
12. Dornan S, Sebestyen Z, Gamble J et al. Differential association
of CD45 isoforms with CD4 and CD8 regulates the actions of
specific pools of p56lck tyrosine kinase in T cell antigen receptor
signal transduction. J Biol Chem 2002; 277: 1912–1918.
13. Bachmann MF, Gallimore A, Linkert S et al. Developmental regu-
lation of Lck targeting to the CD8 coreceptor controls signaling in
naive and memory T cells. J Exp Med 1999; 189: 1521–1530.
14. Viola A. The amplification of TCR signaling by dynamic
membrane microdomains. Trends Immunol 2001; 22: 322–327.
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